February 3, 2022 / Susan Buckles – Envisioning the future of regenerative medicine elicits images of an operating room that also is a manufacturing facility. Patients undergoing surgery could have immediate access to products biomanufactured within the operating room or even within their own bodies.
TGen-Temple comprehensive review highlights recently discovered associations between long noncoding RNAs and specific diseasesContinue reading
Zoey Leipsic joined the AZBio Team in January of 2022 as our Social Media and Communications Intern. In her role, Zoey collects the latest news from our AZBio Member Companies and shares it via posts on AZBio.org as well as on AZBio’s social media accounts so that more people can learn about the important work you do.Continue reading
Paris, February 3, 2022. Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.Continue reading
Perkins Coie attorneys are available to answer questions or discuss legal challenges pertaining to intellectual property and corporate issues that may arise for AZBio Members during “AZBio Office Hours”
The Technology Provides Medical Laboratories with a Rapid (6 hours), Affordable and Accurate Test for the Detection of SARS-CoV-2 (“COVID-19”) and its Variants (“VOC”) and (“VOI”) without Sequencing.
Biden-Harris Administration Sets Goal of Reducing Cancer Death Rate by at least 50 Percent Over the Next 25 Years, and Improving the Experience of Living with and Surviving Cancer
TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress Syndrome (ARDS)/Ventilator Induced Lung Injury (VILI) symptoms in both rat and porcine animal models.
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading
The Arizona Bioindustry Association Board of Directors elected five new directors to its leadership team at its January 2022 meeting. The AZBio Board directs the organization’s key actions and strategies as it pursues its vision of making Arizona a Top-Ten Bioscience State.